Market closed

Regeneron/$REGN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Regeneron

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Ticker

$REGN

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Tarrytown, United States

Employees

14,165

Website

www.regeneron.com

Regeneron Metrics

BasicAdvanced

$77B

17.73 $40.43

0.14 -

Price and volume

Market cap

$77B

Beta

0.14

52-week high

$1,206.81

52-week low

$666.25

Average daily volume

831K

Financial strength

Current ratio

5.281

Quick ratio

4.344

Long term debt to equity

9.221

Total debt to equity

9.221

Interest coverage (TTM)

65.53%

Management effectiveness

Return on assets (TTM)

7.27%

Return on equity (TTM)

17.17%

Valuation

Price to earnings (TTM)

17.733

Price to revenue (TTM)

5.571

Price to book

2.64

Price to tangible book (TTM)

2.74

Price to free cash flow (TTM)

23.239

Growth

Revenue change (TTM)

5.72%

Earnings per share change (TTM)

15.31%

3-year revenue growth (CAGR)

0.74%

3-year earnings per share growth (CAGR)

-13.53%

What the Analysts think about Regeneron

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Regeneron stock.

Regeneron Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Regeneron Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Regeneron News

AllArticlesVideos

Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights

Business Wire·4 hours ago

Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – REGN

Accesswire·7 hours ago

Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman

Accesswire·7 hours ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $REGN

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Regeneron stock?

Regeneron (REGN) has a market cap of $77B as of January 15, 2025.

What is the P/E ratio for Regeneron stock?

The price to earnings (P/E) ratio for Regeneron (REGN) stock is 17.73 as of January 15, 2025.

Does Regeneron stock pay dividends?

No, Regeneron (REGN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Regeneron dividend payment date?

Regeneron (REGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Regeneron?

Regeneron (REGN) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.